NYSE:WST
West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc.'s revenue grew 6.3% in fiscal 2025 to $3.1B while operating margin fell to 19.0%. Free cash flow was $468.9M, 15.3% of revenue, and the diluted share count fell 1.4%.Summary generated from West Pharmaceutical Services Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.1B
Revenue growth+6.3%
Revenue, 5-yr CAGR+7.4%
Gross margin35.9%
Operating margin19.0%
Net margin16.1%
ROIC18.7%
Return on equity16.9%
Debt / equity0.06
Free cash flow$468.9M
FCF margin15.3%
Share count change−1.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2,832 | 2,887 | 2,950 | 2,893 | 3,074 |
| Operating income | 752 | 734 | 676 | 570 | 585 |
| Net income | 662 | 586 | 593 | 493 | 494 |
| Free cash flow | 331 | 439 | 415 | 276 | 469 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 23, 2026 - 8-KResults of operations and financial condition
Jul 23, 2026 - 8-KEntry into a material agreement
Jul 14, 2026 - 8-KDirector or officer change
Jun 1, 2026 - 8-K/AAmended current report
May 20, 2026 - 8-KRegulation FD disclosure
May 11, 2026